Multiple antiviral activities of the antimalarial and anti-hepatitis C drug candidates N-89 and N-251
Authors:
Open Access
- 1 September 2018
- journal article
- research article
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 15, 1-6
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development
This publication has 18 references indexed in Scilit:
- Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free RegimensGastroenterology, 2016
- The cyclic GMP‐AMP synthetase–STING signaling pathway is required for both the innate immune response against HBV and the suppression of HBV assemblyThe FEBS Journal, 2015
- Novel reporter system to monitor early stages of the hepatitis B virus life cycleCancer Science, 2015
- Construction of an infectious molecular clone of Japanese encephalitis virus genotype V and its derivative subgenomic replicon capable of expressing a foreign geneVirus Research, 2015
- Establishment of hepatitis E virus infection‐permissive and ‐non‐permissive human hepatoma PLC/PRF/5 subclonesMicrobiology and Immunology, 2014
- Development of a Novel Dengue-1 Virus Replicon System Expressing Secretory Gaussia luciferase for Analysis of Viral Replication and Discovery of Antiviral DrugsJapanese Journal of Infectious Diseases, 2014
- New Preclinical Antimalarial Drugs Potently Inhibit Hepatitis C Virus Genotype 1b RNA ReplicationPLOS ONE, 2013
- Antimalarial activity of 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol (N-251) and its carboxylic acid derivativesParasitology International, 2011
- Plural assay systems derived from different cell lines and hepatitis C virus strains are required for the objective evaluation of anti-hepatitis C virus reagentsBiochemical and Biophysical Research Communications, 2011
- Synthesis and Antimalarial Activity of Novel Medium-Sized 1,2,4,5-TetraoxacycloalkanesJournal of Medicinal Chemistry, 2001